Thank you to all our Scientific/Medical Advisory Committee members for sharing their time and expertise with us to direct the path of our research program in order to find new treatments and a cure for PSC.
Dr. Dennis Black
Dr. Dennis Black, a pediatric hepatologist, is the James Dustin Buckman Professor of Pediatrics and Professor of Physiology at the University of Tennessee Health Science Center, Memphis. Dr. Black serves as Director of the Children’s Foundation Research Center of Memphis, as well as Vice President for Research for Le Bonheur Children’s Medical Center and Associate Director of the UTHSC Clinical and Translational Science Institute. His research and clinical interests are neonatal lipid metabolism and pediatric liver disease and transplantation. He is Associate Director of the Musette and Allen Morgan, Jr. Foundation for the Study of PSC and Study Chair for the STOPSC multicenter consortium. He has had continuous NIH research funding for the past 18 years. He has served on several grant review committees, including those for the NIH, American Liver Foundation, NASPGHAN, and the American Heart Association. He served as a member of the Editorial Board of the American Journal of Physiology: GI and Liver Physiology from 2003 to 2009.
Dr. Christopher L. Bowlus (Co-chair)
Dr. Christopher Bowlus specializes in the study and treatment of liver diseases, specifically autoimmune liver diseases, including primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH). His research interests are aimed at elucidating the immunogenetic basis of these diseases and developing new therapies for the treatment of these disorders. Dr. Bowlus is currently an Associate Professor and Fellowship Program Director in Gastroenterology and Hepatology at UC Davis Medical Center. Dr. Bowlus received his MD degree from St. Louis University School of Medicine, St. Louis, Missouri, completed his residency in Internal Medicine at the University of California, Davis Medical Center and completed his fellowship in Gastroenterology at Yale University, School of Medicine. Dr. Bowlus is board certified in Gastroenterology and Internal Medicine. Dr. Bowlus has been involved in numerous research studies, including a study for Prometheus Laboratories comparing the prevalence rates of serologic markers in patients with PSC and IBD to PSC without IBD and a matched cohort of IBD without PSC. Dr. Bowlus has published numerous papers.
Dr. Bertus Eksteen
Dr. Eksteen is Associate Professor of Medicine at the University of Calgary and a transplant hepatologist based at the Foothills Medical Centre in Calgary. He was born in South Africa where he completed his basic medical degree before moving to Birmingham in the UK in 1996 where he completed his training in gastroenterology and transplant hepatology. He was elected a Fellow of the Royal College of Physicians of London, UK in 2011. He spent 10 years on the Birmingham liver transplant unit before moving to the University of Calgary in 2011. His main interests are liver transplantation and autoimmune liver diseases such as Primary Sclerosing Cholangitis (PSC). He runs a dedicated multidisciplinary PSC clinic at the Unversity of Calgary Medical Clinics (UCMC) which provides state of the art care for patients from southern Alberta, western Saskatchewan and eastern British Columbia. The clinic is closely aligned with his PSC research program which aims to evaluate new medications for PSC, novel imaging of the colon and bile ducts and the genetics of PSC.
Dr. Greg Everson
Dr. Greg Everson received his MD degree from Cornell Medical College, NY, and is currently Professor of Medicine and Director of Hepatology at the University of Colorado, Denver. Dr. Everson has published over 300 original papers, books, and book chapters in peer-reviewed journals that include Hepatology, Clinics in Liver Disease, Gastroenterology, Journal of Hepatology, New England Journal of Medicine, The American Journal of Gastroenterology, Alimentary Pharmacology and Therapeutics, and Expert Reviews in Gastroenterology and Hepatology. In conjunction with Hedy Weinberg, he has co-authored 5 editions of the popular “self-help” book, Living with Hepatitis C: A Survivor’s Guide, for patients and families. He is an invited speaker and has presented his work at clinical and scientific meetings nationally and internationally. He is a principal investigator for both the HALT-C trial (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) and the A2ALL study (Adult-to-Adult Living Donor Liver Transplantation study) for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), and numerous other clinical trials. Dr. Everson is a member of the American Association for the Study of Liver Diseases (AASLD), the American Society of Transplantation, the International Liver Transplant Society, and the International Association for the Study of the Liver. In addition, he is a member of both the Transplant Hepatology Committee of the American Board of Internal Medicine, and the standing panel for accreditation appeals in the specialty of Internal Medicine/Transplant Hepatology of the Accreditation Council for Graduate Medical Education. He became involved with PSC Partners because Ricky and Don Safer convinced him that the foundation would become a reality and help patients and families.
Dr. Everson is also an honorary member of our Board of Directors.
Dr. Richard Green (Co-chair)
Dr. Richard Green is a Professor of Medicine and Chief of the Section of Hepatology at Northwestern University Feinberg School of Medicine. He graduated with an undergraduate degree from Duke University and subsequently graduated from the Duke University Medical School with a degree in Medicine. He undertook his Internal Medicine training at Northwestern University, where he also served as the Chief Medical Resident. His Gastroenterology and Hepatology Fellowship training was at Brigham and Women’s Hospital at Harvard Medical School, Boston, MA. He subsequently served as an Instructor of Medicine at Brigham and Women’s Hospital and Harvard Medical School, and as an Assistant Professor of Medicine at the University of Illinois in Chicago.
Dr. Green has been actively involved in clinical and basic investigations of cholestatic liver disease, metabolic liver diseases and fatty liver disorders. His current research efforts focus on the genetics and molecular mechanisms of cholestatic and fatty liver disorders. He is the former Chair of the Cholestatic Liver Disorders Special Interest Group (SIG) of the American Association for the Study of Liver Diseases (AASLD), and the former Chair of the Liver-Biliary Council of the American Gastroenterological Association. He also served as an Associate Editor for the journal Hepatology from 2001-2006. He has authored over 50 original articles, book chapters and reviews on a wide range of hepatic disorders.
Dr. Denise M. Harnois
Dr. Denise Harnois received her medical degree from the medical school at Philadelphia College of Osteopathic Medicine, and then received Internal Medicine training at Thomas Jefferson University Hospital. After completing a fellowship in Hepatology and Transplant Medicine at Mayo Clinic, she joined the staff at Mayo Clinic Florida in 1998. Dr. Harnois is board certified in Transplant Hepatology and Gastroenterology and focuses her interest in the areas of cholestatic liver diseases (including primary sclerosing cholangitis) and hepatobiliary malignancies. She has been a well-recognized resource for patients and physicians in her region through her efforts in outreach and academic work in these areas.
Dr. Gideon Hirschfield
Dr. Gideon Hirschfield is a Senior Lecturer at the Centre for Liver Research, University of Birmingham, UK. He trained in the UK where he studied first at Oxford and then at Cambridge University. He has a PhD from the University of London, and completed his Gastroenterology and Hepatology training predominantly while working on the Liver Transplant Program, Addenbrooke`s Hospital, Cambridge. In addition to being a General Transplant Hepatologist, he has a particular interest in autoimmune liver disease and cholestasis, including PSC. His area of research focuses on the development of new treatments for patients, and understanding the basic mechanisms of disease.
Dr. Johannes R. Hov
Dr. Johannes R. Hov is a researcher at the Norwegian PSC Research Center as well as resident in gastroenterology in the Division of Cancer, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet. He received his MD from the University of Oslo in 2003 and a PhD in 2011 with the thesis “Functional genetics in primary sclerosing cholangitis: Studies of the bile acid receptor TGR5 and genes in the HLA complex”.
He is leading the research group “Genomics and metagenomics in inflammatory diseases” (www.ous-research.no/hov) and the main current research focus is the role of gut microbiota in PSC and other inflammatory conditions with gastrointestinal manifestations, in addition to studies of immunogenetics and biomarkers in PSC.
Dr. Keith Lindor
Dr. Keith Lindor is executive vice provost and dean of the College of Health Solutions at Arizona State University (ASU). He focuses on means for improving population health, while lowering costs and enhancing access.
Dr. Lindor joined ASU in January 2012. Before coming to ASU, he served as dean of the Mayo Medical School and was a professor of medicine and chair in the Division of Gastroenterology and Hepatology. He also served as editor-in-chief of Hepatology and was previously the senior associate editor for Clinical Gastroenterology and Hepatology.
Dr. Lindor’s clinical interests include: cholestatic liver diseases in adults, particularly primary biliary cirrhosis and primary sclerosing cholangitis as well as nonalcoholic steatohepatitis.
He received a bachelor’s of chemistry degree from the University of Minnesota and medical degree from Mayo Medical School. He completed his residency in internal medicine at Bowman Grey School of Medicine at Wake Forest University and his gastroenterology fellowship at the Mayo Clinic.
Dr. Stephen Miller
Dr. Stephen Miller graduated magna cum laude with a BS in mathematics from UNISA in South Africa, and summa cum laude with an MD from the University of The Witwatersrand, Johannesburg, South Africa. Dr. Miller completed his residency and completed his board certification in Internal Medicine from Northwestern University, Chicago, IL, and received his fellowship in Clinical Pharmacology from Chicago Medical School. Dr. Miller served as Attending Physician at VA Hospital, North Chicago, Illinois, and Associate Professor, Clinical Medicine and Pharmacology, at Chicago Medical School. Dr. Miller then served as Executive Director, R&D; Senior Director, International Marketing Operations; and Senior Director, International Business Operations and Pharmaceutical Discovery for GD Searle, Inc. in Chicago, IL. Dr. Miller then co-founded and served as Chief Medical Officer of Atlantic Pharmaceuticals, a biotechnology company listed on NASDAQ, until its private acquisition in 2000. Today, Dr. Miller has a tertiary concierge medicine practice and a private equity business (health care infrastructure and services; quantitative securities operations).
Dr. Cyriel Ponsioen
Cyriel Ponsioen was trained as Internist at the Free University Medical Center in Amsterdam from 1989 to 1995. Thereafter he trained as gastroenterologist at the Academic Medical Center (AMC) in Amsterdam from 1995 till 1998. In 2000 he defended his doctoral thesis on Etiological and Clinical Studies in Primary Sclerosing Cholangitis. From 2000-2006 he worked as consultant gastroenterologist in a large teaching hospital. In 2007 he was appointed senior staff member at the Department of Gastroenterology & Hepatology at the AMC. The focus of his clinical as well as research activities lie in inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The former mainly focuses on microbiota research in IBD. As for PSC, he has built up a research line in epidemiology, disease course, and biomarkers, and he leads a research line looking into the relationship between the gut and the biliary tree. He is currently PI of 4 international research projects in PSC including the DILSTENT trial, a randomized trial comparing balloon dilatation versus short-term stenting for dominant strictures in PSC. Within the international PSC Study Group he currently chairs the Clinical Working Group.
Dr. James Tabibian
James grew up in Central California, where he attended UC Davis as an undergraduate majoring in International Relations. He received his M.D. at the Geffen School of Medicine at UCLA, where he graduated with Alpha Omega Alpha honors. He then completed Internal Medicine training in the Osler Medical Housestaff Program at Johns Hopkins. Thereafter, James was accepted as the first joint NIH T32 track/ABIM Subspecialty Research Pathway fellow in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, MN. While completing clinical training, James successfully defended a PhD thesis entitled, “Etiopathogenesis, modeling, and treatment of primary sclerosing cholangitis (PSC)” through Mayo Graduate School, Center for Clinical and Translational Studies (CTSA), under the mentorship of Drs. Nicholas F. LaRusso and Keith D. Lindor. In addition, James was a Co-Principle Investigator of the 2013 PSC Partners Seeking a Cure Annual Research Grant and the 2014 distinguished AASLD Clinical and Translational Research Award. Following his training at Mayo Clinic, James was an Instructor and Advanced Endoscopy Fellow at the University of Pennsylvania, where he spent a year teaching endoscopy to GI fellows and learning specialized techniques such as ERCP, EUS-FNA, cholangioscopy, and others.
As of June 2016, James moved to Sacramento to join the faculty of the UC Davis Medical Center as an Assistant Professor and Director of Fellow Research. His academic interests remain centered around clinico-translational and endoscopic aspects of cholestatic liver disease, and he is actively involved in both clinical care and patient-oriented research, with a particular focus on PSC and other cholangiopathies.